BioArctic AB Receives Significant Royalty from Leqembi Sales
Stockholm, July 31, 2025 — BioArctic AB, a research-intensive biopharmaceutical company based in Stockholm, Sweden, has reported a substantial increase in royalties from the sales of Leqembi, a treatment for Alzheimer’s disease. Partnering with Eisai Co., Ltd., BioArctic received a royalty of 162.5 million SEK for the second quarter of 2025. This follows the announcement of global sales figures for Leqembi, which reached 23.1 billion yen during the same period.
The financial boost from these royalties has positively impacted BioArctic’s stock performance. On the Swedish Stock Exchange, BioArctic’s shares rose following the news, while the OMXS30 index experienced a slight decline of 0.5 percent. This development underscores the growing commercial success of Leqembi, which is co-developed by Eisai and Biogen.
In addition to financial gains, the latest clinical data presented at the Alzheimer’s Association International Conference (AAIC) in Toronto has reinforced the clinical efficacy of Leqembi. The findings, shared by Eisai, highlight the treatment’s consistent safety profile, further strengthening its position in the market.
BioArctic continues to focus on developing innovative treatments for neurodegenerative diseases, with several promising projects in various stages of clinical trials. These include BAN2401, targeting toxic amyloid-beta oligomers in Alzheimer’s disease, and BAN0805, an anti-alpha-synuclein treatment for Parkinson’s disease. The company’s commitment to advancing disease-modifying therapies and diagnostics remains a cornerstone of its strategy.
With a market capitalization of 16.28 billion SEK and a price-to-earnings ratio of 21.54, BioArctic is well-positioned to capitalize on its ongoing research and development efforts. The company’s collaborations with industry leaders like Eisai and AbbVie Inc., along with its research partnership with Brain Biomarker Solutions in Gothenburg AB, further enhance its capabilities in the biotechnology sector.
As BioArctic continues to navigate the competitive landscape of the healthcare industry, its focus on innovative solutions for neurodegenerative diseases positions it as a key player in the field. The recent financial and clinical developments surrounding Leqembi are indicative of the company’s potential for sustained growth and impact.